The 47th San Antonio Breast Cancer Symposium (SABCS) will be held from December 10 to 13, 2024, in San Antonio, USA. A phase II prospective study led by Professors Huiping Li and Hanfang Jiang from Peking University Cancer Hospital will be presented as a poster (Abstract No: P1-02-12). This study explores the efficacy and safety of hetrombopag monotherapy in treating cancer therapy-induced thrombocytopenia (CTIT) in breast cancer patients. Preliminary findings show that hetrombopag achieves a high treatment response rate, rapidly improves platelet (PLT) levels, and demonstrates excellent efficacy and tolerance without severe adverse events, particularly no thrombosis. These results confirm the potential of hetrombopag as a novel therapeutic option for CTIT in breast cancer patients, providing new evidence-based data. As the research progresses, hetrombopag is expected to play a greater role in improving treatment outcomes for breast cancer patients undergoing antitumor therapy.